Португалия - португальский - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - darunavir - comprimido revestido por película - 600 mg - propilenoglicolato de darunavir 683.34 mg - darunavir - genérico - duração do tratamento: longa duração

Европейский союз - португальский - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - infecções por hiv - antivirais para uso sistêmico - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Европейский союз - португальский - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - maribavir - infecções por citomegalovírus - antivirais para uso sistêmico - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). deve ser tido em consideração a orientação oficial sobre o uso apropriado de agentes antivirais.

Европейский союз - португальский - EMA (European Medicines Agency)

janssen-cilag international n.v. - darunavir, cobicistat - infecções por hiv - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - rezolsta, é indicado em combinação com outros medicamentos anti-retrovirais para o tratamento da infecção pelo vírus 1 da imunodeficiência humana (hiv 1) em adultos com idade igual ou superior a 18 anos. genotypic testes devem orientar o uso de rezolsta.

Европейский союз - португальский - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir, cobicistat, emtricitabina, tenofovir alafenamide - infecções por hiv - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - a symtuza é indicada para o tratamento da infecção pelo vírus do vírus da imunodeficiência humana tipo 1 (hiv-1) em adultos e adolescentes (com idade igual ou superior a 12 kg com peso corporal de pelo menos 40 kg). genotypic testing should guide the use of symtuza.

Бразилия - португальский - ANVISA (Agência Nacional de Vigilância Sanitária)

janssen-cilag farmacÊutica ltda - etanolato de darunavir, cobicistate, entricitabina, hemifumarato de tenofovir alafenamida - associaÇÕes de antivirÓticos para o tratamento de infecÇÕes por hiv

Бразилия - португальский - ANVISA (Agência Nacional de Vigilância Sanitária)

janssen-cilag farmacÊutica ltda - etanolato de darunavir - antiretroviral

Бразилия - португальский - ANVISA (Agência Nacional de Vigilância Sanitária)

cristÁlia produtos quÍmicos farmacÊuticos ltda. - propilenoglicolato de darunavir - antiretroviral

Бразилия - португальский - ANVISA (Agência Nacional de Vigilância Sanitária)

takeda pharma ltda. - maribavir - antiviroticos

Европейский союз - португальский - EMA (European Medicines Agency)

gilead sciences ireland uc - cobicistat - infecções por hiv - antivirais para uso sistêmico - tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (hiv-1) infected adults and adolescents aged 12 years and older:weighing at least 35 kg co‑administered with atazanavir orweighing at least 40 kg co‑administered with darunavir.